CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma

Joseph D. Malaer, Porunelloor Mathew

Research output: Contribution to journalReview article

16 Scopus citations

Abstract

CS1 (also known as CD319, CRACC and SLAMF7) was identified as an NK cell receptor regulating immune functions. It is also expressed on B cells, T cells, Dendritic cells, NK-T cells, and monocytes. CS1 is overexpressed in multiple myeloma and makes it a target for immunotherapy. A humanized anti-CS1 antibody, Elotuzumab or Empliciti has shown promising results in clinical studies. This review focuses on the biology of CS1 in NK and other hematopoietic cells and multiple myeloma. Anti-CS1 mAb can activate natural cytotoxicity of NK cells as well as enhance ADCC (antibody-dependent cell-mediated cytotoxicity) and thus makes an effective target for immunotherapy of MM.

Original languageEnglish
Pages (from-to)1637-1641
Number of pages5
JournalAmerican Journal of Cancer Research
Volume7
Issue number8
StatePublished - 1 Jan 2017

Keywords

  • Antibody-based immunotherapy
  • CRACC
  • CS1
  • Elotuzumab
  • Multiple myeloma
  • SLAMF7

Fingerprint Dive into the research topics of 'CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma'. Together they form a unique fingerprint.

  • Cite this